Improving Clinical Outcomes For Faster Approvals
The immune checkpoint inhibitor market has been labeled a sector which could stand alone as a multi-billion dollar industry in the next 10 years. Unsurprisingly, the therapeutic has attracted the attention of many in pharma, fuelling what has emerged as an R&D race, with many players teaming up in the bid to produce a blockbuster treatment.It is estimated that it can take over 15 years to develop, test and license a new drug with sometimes billions spent on funding t...
TO READ THE FULL STORY
Please note: That all fields marked with an asterisk (*) are required.